Daniel Friedman is a Principal on BroadOak’s growth capital investing team where he specializes in portfolio management and investment execution. Prior to joining BroadOak in 2019, Daniel worked for Raymond James within the Life Sciences Investment Banking team where he focused on public financings and M&A for biotechnology and medical device companies. Daniel currently serves as a Board Director at PBS Biotech and as Secretary of the Board at Biolog. Daniel previously acted as a board observer at both Avidien Technologies and antibodies-online.

Daniel earned a B.B.A. with concentrations in finance and accounting from the Ross School of Business at the University of Michigan.